COMMUNIQUÉS West-GlobeNewswire

Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium
25/01/2024
WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial [...]
Increase of 2023 revenue at €10.5 million
25/01/2024
Press release Ecully, January 25, 2024 – 6.00 p.m. 2023 revenue of €10.5 million In thousands of euros Unaudited data 2023 2022 % change Q1 revenue 2,399 1,342 +79% Q2 revenue 3,034 1,770 +71% Q3 revenue 2,077 2,249 -8 [...]
Hausse du Chiffres d'affaires annuel à 10,5 millions d'euros
25/01/2024
Communiqué de presse Ecully, le 25 janvier 2024 – 18h00 Chiffre d’affaires 2023 de 10,5 M€ En milliers d’euros Chiffres non audités 2023 2022 Variation 2023/2022 CA 1 er trimestre 2 399 1 342 + 79% CA 2 e trimestre 3 [...]
European Bioplastics Calls for Action to Accelerate Biopolymers Industrial Growth
25/01/2024
BRUSSELS, Belgium, Jan. 25, 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP) released its Policy Manifesto today, calling on the European Union (EU) to develop a comprehensive Biopolymers Industrial Action Plan to [...]
European Bioplastics lance un appel à l'action pour accélérer la croissance industrielle des biopolymères
25/01/2024
BRUXELLES, Belgique, 25 janv. 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP) a publié aujourd'hui son manifeste politique, appelant l'Union européenne (UE) à développer un plan d'action industriel complet pour les [...]
QIAGEN announces partnership with Penn State University to advance microbiome sciences
25/01/2024
Partnership aims to help shape research, education and outreach in microbiomes – the community of microorganisms within an environment // QIAGEN to provide instruments and solutions for shared research and education [...]
Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions
25/01/2024
Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million [...]
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
25/01/2024
Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors refractory to TCR [...]
Wellness Redefined: Return Healthy Launches Unique Approach to Enhancing Physical, Mental, and Emotional Resilience
25/01/2024
St. George, Utah, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Return Healthy is proud to announce the launch of its new website and revolutionary approach to holistic wellness designed to help individuals enhance their physical [...]
Castellum Announces Pricing of $2.7 Million Registered Direct Offering
25/01/2024
BETHESDA, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government today announced [...]
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
25/01/2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a [...]
Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.
25/01/2024
Grants, New Mexico, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) today announced the agreement to purchase assets from C2 Wellness Corporation. (“C2”), a Wyoming registered company with an [...]
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
25/01/2024
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical [...]
NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
25/01/2024
Project to benefit from Scorpius’ comprehensive services in process development, bioanalysis, and cGMP manufacturing DURHAM, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“ [...]
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
25/01/2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing [...]
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
25/01/2024
Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration NGC-Cap was better tolerated with positive preliminary [...]
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
25/01/2024
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced [...]
Evaxion développe de nouveaux vaccins personnalisés contre le cancer basés sur une nouvelle source inexploitée de cibles découvertes par l’IA
25/01/2024
Des vaccins sur mesure : avec la découverte de ces nouveaux types de cibles vaccinales contre le cancer grâce à AI-Immunology™, la conception de solutions vaccinales personnalisées et de précision devient réalisable et [...]
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
25/01/2024
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis [...]

Pages